<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02992496</url>
  </required_header>
  <id_info>
    <org_study_id>v1.2_20161024</org_study_id>
    <nct_id>NCT02992496</nct_id>
  </id_info>
  <brief_title>Investigation of Antidepressant Efficacy of Oral Ketamine Treatment</brief_title>
  <official_title>Investigation of Antidepressant Efficacy of Oral Ketamine Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this double-blind, controlled, randomized study is to investigate the
      antidepressant efficacy of oral ketamine treatment in patients suffering from a major
      depressive episode.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 24, 2017</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Montgomery-Åsberg Depression Rating Scale (MADRS)</measure>
    <time_frame>1 week</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinician Administered Dissociative States Scale (CADSS)</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hamilton Depression Rating Scale</measure>
    <time_frame>1 week</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Major Depressive Episode</condition>
  <arm_group>
    <arm_group_label>Ketamine treatment group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Each patient will undergo six treatment sessions with 1mg/kg oral ketamine over 2 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Each patient will undergo six treatment sessions with 0.03mg/kg oral midazolam over 2 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>1mg/kg, 6 applications over 2 weeks</description>
    <arm_group_label>Ketamine treatment group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam Hydrochloride</intervention_name>
    <description>0.03mg/kg, 6 applications over 2 weeks</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of a major depressive episode in the scope of a major depressive or bipolar
             disorder supported by a Structured Clinical Interview for DSM-IV-TR (SCID)

          -  Hamilton depression rating scale score ≥ 19

          -  Willingness and competence to sign the informed consent form

          -  Stable psychopharmacological treatment for 10 days (except benzodiazepines)

        Exclusion Criteria:

          -  Initiation of a new antidepressant or mood stabilizing treatment (pharmacological,
             physical or psychotherapeutic) with adequate dosage (as defined by the minimum
             recommended dose in the respective prescribing information) within 4 weeks prior to
             inclusion

          -  Prior use of ketamine

          -  Pregnancy/Breast feeding

          -  Instable arterial hypertension &gt;170/110mmHg

          -  Hepatic dysfunction

          -  Hyperthyreosis

          -  History of glaucoma

          -  Neurodegenerative disorders

          -  Any unstable medical illness

          -  History of substance abuse within the past 12 months

          -  History of psychosis

          -  Failure to comply with the study protocol or to follow the instructions of the
             investigating team

          -  Current treatment with one of the following drugs: clopidogrel, carbamazepine,
             valproate, barbiturates, memantine, modafinil, disulfiram, amiodarone, ranolazine,
             phenytoin, verapamil, fibrates, antiretroviral agents, antimicrobial
             chemotherapeutics, azole antifungals, glucocorticoids, cyclosporine,
             valeriana/garlic/grapefruit preparations, St. John's wort.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Psychiatry and Psychotherapy, Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rupert Lanzenberger, A/Prof.</last_name>
      <phone>+43 40400</phone>
      <phone_ext>35760</phone_ext>
      <email>rupert.lanzenberger@meduniwien.ac.at</email>
    </contact>
    <investigator>
      <last_name>Rupert Lanzenberger, A/Prof. MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 12, 2016</study_first_submitted>
  <study_first_submitted_qc>December 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 14, 2016</study_first_posted>
  <last_update_submitted>March 30, 2018</last_update_submitted>
  <last_update_submitted_qc>March 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Rupert Lanzenberger</investigator_full_name>
    <investigator_title>Assoc.-Prof., MD PD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Antidepressive Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

